Vascular Endothelial Growth Factor A Competitively Inhibits Platelet-Derived Growth Factor (PDGF)-Dependent Activation of PDGF Receptor and Subsequent Signaling Events and Cellular Responses

ABSTRACT Certain platelet-derived growth factor (PDGF) isoforms are associated with proliferative vitreoretinopathy (PVR), a sight-threatening complication that develops in a subset of patients recovering from retinal reattachment surgery. Although these PDGF isoforms are abundant in the vitreous of patients and experimental animals with PVR, they make only a minor contribution to activating PDGF receptor α (PDGFRα) and driving experimental PVR. Rather, growth factors outside of the PDGF family are the primary (and indirect) agonists of PDGFRα. These observations beg the question of why vitreal PDGFs fail to activate PDGFRα. We report here that vitreous contains an inhibitor of PDGF-dependent activation of PDGFRα and that a major portion of this inhibitory activity is due to vascular endothelial cell growth factor A (VEGF-A). Furthermore, recombinant VEGF-A competitively blocks PDGF-dependent binding and activation of PDGFR, signaling events, and cellular responses. These findings unveil a previously unappreciated relationship between distant members of the PDGF/VEGF family that may contribute to pathogenesis of a blinding eye disease.

[1]  S. Mukai,et al.  Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells. , 2011, Investigative ophthalmology & visual science.

[2]  S. Mukai,et al.  A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. , 2011, The American journal of pathology.

[3]  A. Kazlauskas,et al.  Pathological Signaling via Platelet-Derived Growth Factor Receptor α Involves Chronic Activation of Akt and Suppression of p53 , 2011, Molecular and Cellular Biology.

[4]  G. Lozano,et al.  Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo , 2011, The Journal of pathology.

[5]  A. Levine,et al.  p53 and NF‐κB: different strategies for responding to stress lead to a functional antagonism , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  A. Kazlauskas,et al.  Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. , 2010, Experimental eye research.

[7]  T. Hirose,et al.  Growth factors outside the PDGF family drive experimental PVR. , 2009, Investigative ophthalmology & visual science.

[8]  A. Kazlauskas,et al.  Growth Factors Outside of the Platelet-derived Growth Factor (PDGF) Family Employ Reactive Oxygen Species/Src Family Kinases to Activate PDGF Receptor α and Thereby Promote Proliferation and Survival of Cells* , 2009, Journal of Biological Chemistry.

[9]  D. Nikolov,et al.  Cell-cell signaling via Eph receptors and ephrins. , 2007, Current opinion in cell biology.

[10]  J. C. Kim,et al.  Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy , 2007, Eye.

[11]  A. Liem,et al.  Balance of Vascular Endothelial Growth Factor and Pigment Epithelial Growth Factor prior to Development of Proliferative Vitreoretinopathy , 2007, Ophthalmic Research.

[12]  C. Kielty,et al.  Vascular endothelial growth factor can signal through platelet-derived growth factor receptors , 2007, The Journal of cell biology.

[13]  R. Scott,et al.  Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. , 2007, Investigative ophthalmology & visual science.

[14]  T. Hirose,et al.  A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. , 2007, Investigative ophthalmology & visual science.

[15]  S. Mukherjee,et al.  The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. , 2007, Investigative ophthalmology & visual science.

[16]  G. Carpenter,et al.  ErbB receptors: new insights on mechanisms and biology. , 2006, Trends in cell biology.

[17]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[18]  T. Harada,et al.  The role of cytokines and trophic factors in epiretinal membranes: Involvement of signal transduction in glial cells , 2006, Progress in Retinal and Eye Research.

[19]  J. Lillehaug,et al.  Structural and functional specificities of PDGF‐C and PDGF‐D, the novel members of the platelet‐derived growth factors family , 2005, The FEBS journal.

[20]  J. Matsubara,et al.  Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy , 2005, Eye.

[21]  F. Doran,et al.  Interleukin (IL)-6, Interleukin (IL)-8 Levels and Cellular Composition of the Vitreous Humor in Proliferative Diabetic Retinopathy, Proliferative Vitreoretinopathy, and Traumatic Proliferative Vitreoretinopathy , 2005, Ocular immunology and inflammation.

[22]  U. Eriksson,et al.  The PDGF family: four gene products form five dimeric isoforms. , 2004, Cytokine & growth factor reviews.

[23]  C. Bruyns,et al.  IL-10 in vivo gene expression in a cell-induced animal model of proliferative vitreoretinopathy. , 2003, International journal of molecular medicine.

[24]  Y. Tano,et al.  Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. , 2003, Japanese journal of ophthalmology.

[25]  A. Liem,et al.  Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. , 2002, American journal of ophthalmology.

[26]  E. Barrón,et al.  Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy , 2002, Eye.

[27]  Y. Ikuno,et al.  An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. , 2002, Investigative ophthalmology & visual science.

[28]  M. Moore,et al.  Platelet-derived Growth Factor C (PDGF-C), a Novel Growth Factor That Binds to PDGF α and β Receptor* , 2001, The Journal of Biological Chemistry.

[29]  H. Dua,et al.  Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy , 2001, The British journal of ophthalmology.

[30]  Y. Ikuno,et al.  Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. , 2000, Investigative ophthalmology & visual science.

[31]  Paige L. Jensen.  Eph Receptors and Ephrins , 2000, Stem cells.

[32]  M. Refojo,et al.  Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. , 1999, Investigative ophthalmology & visual science.

[33]  N. Rahimi,et al.  A role for cadherin-5 in regulation of vascular endothelial growth factor receptor 2 activity in endothelial cells. , 1999, Molecular biology of the cell.

[34]  P. Khaw,et al.  Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. , 1999, Investigative ophthalmology & visual science.

[35]  F. Grinnell,et al.  Differences in the Regulation of Fibroblast Contraction of Floating Versus Stressed Collagen Matrices* , 1999, The Journal of Biological Chemistry.

[36]  D. Stern,et al.  Activation of Neu (ErbB-2) Mediated by Disulfide Bond-Induced Dimerization Reveals a Receptor Tyrosine Kinase Dimer Interface , 1998, Molecular and Cellular Biology.

[37]  J. Pastor,et al.  Proliferative vitreoretinopathy: an overview. , 1998, Survey of ophthalmology.

[38]  D. Charteris.  Growth factors in proliferative vitreoretinopathy , 1998, The British journal of ophthalmology.

[39]  B. Keyt,et al.  The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. , 1997, Structure.

[40]  A. D. de Vos,et al.  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[42]  P. Campochiaro,et al.  Pathogenic mechanisms in proliferative vitreoretinopathy. , 1997, Archives of ophthalmology.

[43]  L. Cantley,et al.  Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity , 1996, Molecular and cellular biology.

[44]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[46]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[47]  J. Robertson,et al.  Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. , 1994, Investigative ophthalmology & visual science.

[48]  S. Wahab.  Traction retinal detachment. XLIX Edward Jackson Memorial Lecture. , 1994, American journal of ophthalmology.

[49]  F. Winkler,et al.  Crystal structure of human platelet‐derived growth factor BB. , 1992, The EMBO journal.

[50]  P. Phillips,et al.  Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. , 1989, The Journal of biological chemistry.

[51]  R. Ross,et al.  Two classes of PDGF receptor recognize different isoforms of PDGF. , 1988, Science.

[52]  B. Glaser,et al.  Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. , 1987, Ophthalmology.

[53]  C. Stiles,et al.  Purification of human platelet-derived growth factor. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Machemer,et al.  Glial cell proliferation in retinal detachment (massive periretinal proliferation). , 1975, American journal of ophthalmology.

[55]  G. Barile,et al.  Proliferative vitreoretinopathy. , 2007, Ophthalmology.

[56]  Y. Ikuno,et al.  TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGFalpha receptor. , 2002, Investigative ophthalmology & visual science.

[57]  M. Moore,et al.  Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. , 2001, The Journal of biological chemistry.

[58]  N. Rahimi,et al.  Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. , 1999, Investigative ophthalmology & visual science.

[59]  R. Strieter,et al.  Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. , 1995, Current eye research.

[60]  P. Gastaud,et al.  Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. , 1993, Ophthalmic research.

[61]  R. Ross,et al.  Methods for studying the platelet-derived growth factor receptor. , 1985, Methods in enzymology.

[62]  J. Matsubara,et al.  Epithelial and Mesenchymal Cell Biology N-Acetylcysteine Suppresses Retinal Detachment in an Experimental Model of Proliferative Vitreoretinopathy , 2022 .